JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition
The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022
The drug is priced at Rs 2000 for a course of 40 tablets
The transaction is expected to close in the first quarter of 2022
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
It is the generic version of molnupiravir
The brand is now available pan-India through their distribution partner
PeproTech's recombinant proteins portfolio complements Thermo Fisher's cell culture media products
Subscribe To Our Newsletter & Stay Updated
